文献速递糖尿病

早期代谢终点可识别新发1型糖尿病免疫治疗试验的持续疗效

Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
PubMed 文献 · Diabetes Care · 2024-01-01

该事后分析纳入6项1型糖尿病试验网(TrialNet)免疫治疗随机对照试验,评估除C肽曲线下面积(AUC)外的刺激代谢指标。在达到主要终点的试验中,3个月和6个月C肽AUC动态变化可检出治疗效应(P=0.030和P<0.001),6个月动态指标对12个月C肽AUC有预测价值(调整后R²=0.80,P<0.001),支持样本量可小至54例。

要点

  • 在达到主要终点的试验中,3个月和6个月C肽AUC动态变化可检出治疗效应。
  • 未成功的试验中未观察到上述差异。
  • 6个月C肽AUC动态指标可预测12个月C肽保存,支持样本量小至54例。

核心结论

  • 早期动态指标可在成功的免疫治疗试验中识别治疗效应,并具有较好的长期预测能力和实用的样本量。
  • 作者认为,虽然需要外部验证,但已有强有力的理由和数据支持缩短早期临床试验。

研究设计与样本

  • 对6项1型糖尿病试验网(TrialNet)免疫治疗随机对照试验进行事后分析,纳入除C肽AUC外的额外刺激代谢指标。
  • 分析分为成功与未成功试验,并分别进行汇总分析和各试验单独分析。

主要发现

  • 在达到主要终点的试验中,使用C肽AUC作为动态指标(即从基线的变化)在3个月和6个月识别出治疗效应(分别为P=0.030和P<0.001)。
  • 在未成功的试验中未观察到此类差异。
  • 使用6个月C肽AUC动态指标不仅检测到治疗效应,还提示长期C肽保存(经年龄和基线值调整的12个月C肽AUC的R²为0.80,P<0.001)。
  • 该发现支持样本量可小至54名参与者的试验概念。

局限性

  • 原文指出需要对这些发现进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mixed-meal tolerance test-stimulated area under the curve (AUC) C-peptide at 12-24 months represents the primary end point for nearly all intervention trials seeking to preserve β-cell function in recent-onset type 1 diabetes. We hypothesized that participant benefit might be detected earlier and predict outcomes at 12 months posttherapy. Such findings would support shorter trials to establish initial efficacy. RESEARCH DESIGN AND METHODS: We examined data from six Type 1 Diabetes TrialNet immunotherapy randomized controlled trials in a post hoc analysis and included additional stimulated metabolic indices beyond C-peptide AUC. We partitioned the analysis into successful and unsuccessful trials and analyzed the data both in the aggregate as well as individually for each trial. RESULTS: Among trials meeting their primary end point, we identified a treatment effect at 3 and 6 months when using C-peptide AUC (P = 0.030 and P < 0.001, respectively) as a dynamic measure (i.e., change from baseline). Importantly, no such difference was seen in the unsuccessful trials. The use of C-peptide AUC as a 6-month dynamic measure not only detected treatment efficacy but also suggested long-term C-peptide preservation (R2 for 12-month C-peptide AUC adjusted for age and baseline value was 0.80, P < 0.001), and this finding supported the concept of smaller trial sizes down to 54 participants. CONCLUSIONS: Early dynamic measures can identify a treatment effect among successful immune therapies in type 1 diabetes trials with good long-term prediction and practical sample size over a 6-month period. While external validation of these findings is required, strong rationale and data exist in support of shortening early-phase clinical trials.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Jacobsen LM, Cuthbertson D, Bundy BN, et al. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care. 2024. PMID: 38621411. doi:10.2337/dc24-0171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。